Cell Therapy and Gene Therapy Markets

Cell Therapy and Gene Therapy Markets

This is an exciting and interesting time in the cell and gene therapy industry. The science is moving ahead as industry industrializes and standardizes the manufacturing and commercialization of products. Cell and gene therapy products are transforming the treatment of cancers and genetic diseases, as well as expanding into other areas of medicine including autoimmune diseases, cardiovascular diseases, musculoskeletal disease, dermatological diseases, and many others. Cell Therapy and Gene Therapy Markets presents the market in segments that provide an overview of disease epidemiology, market estimates and forecasts, and competitive summary of leading providers:

  • Cell and Gene Therapy Market Summary by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular - Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total Market)
  • Cell and Gene Therapy Market Summary by Method, 2020-2030 ($ millions) (Cell Therapy, Gene Therapy, Total Market)
  • Cell and Gene Therapy Market Summary by Geographical Region, 2020-2030 ($ millions) (United States, Europe/European Union, Other Countries, Global Market)
  • Cell and Gene Therapy Market Summary for United States by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular - Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
  • U.S. Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
  • Europe Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
  • Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
  • Estimated Cell and Gene Therapy Sales by Leading Competitor, 2019 Sales ($ millions)
The report examines developments in cell and gene therapy markets by condition/disorder, including principal products, trends in research and development, market breakdown of cell and gene therapies, regional market summary, and competitor summary. The following conditions/disorders are covered:
  • Dermatology, including:
  • Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Skin cells)
  • Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Wound healing/treatment, Other indications [wrinkles, scar treatment])
  • Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
  • Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)
  • Cardiovascular and Blood Disorders, including:
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapies; Stromal cells)
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Cardiac disorders, Vascular disorders, Blood disorders, Hypercholesterolemia)
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, S. Korea, Japan, ROW)
  • Oncology, including:
  • Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
  • Oncology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Blood cancers, Prostate cancer, Melanoma, Other cancers)
  • Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, ROW)
  • Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)
  • Ophthalmic Conditions, including:
  • Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapy)
  • Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, Other countries)
  • Musculoskeletal Conditions and Disorders, including:
  • Musculoskeletal Cell Therapy Market, Estimated 2020 and Projected 2025 and 2030 ($ millions)
  • Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
  • Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
  • Musculoskeletal Cell Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)
  • Other Conditions, including:
  • Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Cell therapy, Gene therapy, Gene-modified cell therapy)
  • Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
Cell Therapy and Gene Therapy Markets also includes several discussions on cell and gene therapies in development and the impact these are expected to have on the market. Throughout the report, several market indicators, trends, and barriers are discussed.

The report comments on the current COVID-19 cell and gene therapy pipeline. There are a number of companies that are responding to the call to develop a therapeutic or vaccine for the coronavirus, including:
  • Vitro Biopharma
  • Celularity and Sorrento Therapeutics
  • CanSino Biologics
  • Mesoblast
  • Acturus Therapeutics
  • Entos Pharmaceuticals
  • Zydus Cadila
  • AlloVir and Baylor College of Medicine
  • Athersys
  • Exothera
  • Sirnaomics
  • Mesoblast
  • The leading influencers in the market are those which have become first-to-market participants in the cell and gene therapy segment, have new developments which may disrupt current market conditions, and/or have an extensive pipeline sure to impact the market in the long-term forecast:
  • Advantagene
  • Advaxis
  • AlloSource
  • Alnylam Pharmaceuticals
  • Amgen
  • AnGes USA
  • Anterogen
  • Atara Therapeutics
  • Athersys
  • AveXis
  • BioCardia
  • BioMarin Pharmaceuticals
  • Bluebird bio
  • BrainStorm Cell Therapeutics
  • Caladrius Bioscience
  • Celyad
  • Cook MyoSite
  • Cytori Therapeutics
  • Dendreon
  • Ferring Pharmaceuticals
  • Fibrocell
  • Gamida Cell
  • GenSight Biologics
  • Genzyme
  • Gilead Sciences
  • Gradalis
  • Inovio Pharmaceuticals
  • Kiadis Pharma
  • Medeor Therapeutics
  • Medipost
  • Merck
  • Mesoblast
  • MolMed
  • Neurotech USA
  • Nightstar Therapeutics
  • Northwest Biotherapeutics
  • Novartis
  • NuVasive
  • Orchard Therapeutics
  • Organogenesis
  • Orthofix
  • Osiris Therapeutics (part of Smith & Nephew)
  • Pharmicell
  • Pluristem Therapeutics
  • Quark Pharmaceuticals
  • Renova Therapeutics
  • Sanofi Pasteur
  • SOTIO
  • Spark Therapeutics
  • Tessa Therapeutics
  • Tocagen
  • uniQure
  • VBL Therapeutics
  • ViroMed
Because gene therapies are currently not available in any wide capacity, there is little precedent upon which to base forecasts. Dollar figures represent the estimated global market for 2019 and expected market for 2020 based on first quarter company reports and is expressed in current dollars. Forecasts are provided through 2025 and an extended forecast for 2030. The size of each market segment refers to manufacturers’ revenues.

*Note: The full report pricing option allows for 1-10 users in a single department*


  • Executive Summary
    • Overview
    • Scope and Methodology
    • Market Overview and Potential
    • Coronavirus Cell and Gene Therapy Pipeline
  • Introduction to Cell and Gene Therapy
    • Introduction
      • Cell Therapy
        • Table Adult vs. Embryonic Stem Cells
      • Gene Therapy
        • Table Somatic vs. Germ Line Gene Therapy
      • Viral Vector System and New Developments
        • Table Examples of Viruses in Gene Therapy
        • Table Gene Therapy Vector Type Distribution, Commercialized (current and former) Products (%)
      • Non-viral Systems for Transporting Genes
      • Gene Editing
    • Cell and Gene Therapy: Characteristics
      • Table Cell Therapy vs. Gene Therapy
      • Table Autologous vs. Allogeneic Cell and Gene Therapies, Commercialized Products
      • Table Cell and Gene Therapy, Autologous and Allogeneic Distribution for Commercialized Products (%)
      • Table Cell and Gene Therapy (combined autologous and allogeneic), Route of Administration Distribution for Commercialized Products (%)
    • Staffing
    • Manufacturing Process for CAR-T
      • Leukapheresis
      • Activation
      • Transduction
      • Expansion
    • Advancements and Barriers in Manufacturing Processes
      • Table Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
      • Table Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
    • Cost
    • Reimbursement
    • Logistics
    • Mergers and Acquisitions
      • Table Select Company Mergers and Acquisitions in the Cell and Gene Therapy Market
    • Regulatory Developments
      • Fast Track
      • Orphan Drug
      • Breakthrough Therapy
      • Accelerated Approval
      • Priority Review
        • Table Regulatory Actions and Guidelines for Cell and Gene Therapy by Select Country
      • Individualized Gene Therapy Approval Process
    • Development and Pipeline Overview
    • Development Progress
      • Table Global Cell and Gene Therapy Development Progress (phase I through phase III)
      • Table Global Cell and Gene Therapy Development Progress by Phase (%)
    • Development by Condition/Disorder
      • Table Global Development of Cell and Gene Therapies by Target (%)
    • Phase III Development
      • Table Phase III Development  Cell and Gene Therapies, Select Projects
      • Table Cell and Gene Therapy: Top 30 Developers (Phase I through Submission)
    • End User
      • Hospitals
      • Research Institutes
      • Wound Care Centers
      • Cancer Centers
  • Cell and Gene Therapy Markets in Dermatology
    • Overview
      • Table Wound Prevalence by Type
    • Market Outlook
      • Table Cell and Gene Therapy Markets in Dermatology, 2019-2030 ($ millions)
    • Principal Products
      • Apligraf
      • CureSkin
      • Dermagraft
      • Epicel
      • Gintuit
      • Grafix
      • Holoderm
      • Kaloderm
      • KeraHeal/KeraHeal-Allo
      • LaViv
      • Orcel
      • Quencell
      • RECELL
      • Rosmir
      • Stravix
      • TransCyte
        • Table Cell and Gene Therapy in Dermatological Diseases and Disorders
        • Table Dermatology Cell and Gene Therapy Approvals by Year or Year Range, through 2019
    • Trends in Research and Development
      • Table Dermatology Cell and Gene Therapies in Development by Phase (%), March 2020 Data
      • Table Dermatology Cell and Gene Therapies in Development by Method (%), March 2020 Data
    • Market Breakdown of Cell and Gene Therapies
      • Table Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions)
      • Table Dermatology Cell and Gene Therapy Markets by Product Type, 2017 - 2030 ($ millions)
      • Table Dermatology Cell and Gene Therapy Market Distribution by Product Type, 2020 (%)
      • Dermatology Cell and Gene Therapy Market by Indication
        • Table Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions)
        • Table Dermatology Cell and Gene Therapy Market by General Indication, 2017 - 2030 ($ millions)
    • Regional Market Summary
      • Table Dermatology Cell and Gene Therapy Approvals by Country/Region, through 2019
      • Table Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions)
      • Table Dermatology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions)
    • Competitor Summary
      • Table Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)
  • Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders
    • Overview
      • Cardiovascular Disease
      • Selected Blood Disorders
    • Market Outlook
      • Table Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders, 2019-2030 ($ millions)
    • Principal Products
      • Collategene
      • Hearticellgram
      • HeartSheet
      • Neovasculgen
      • Stempeucel
      • Zynteglo
      • Cord Blood Products
        • Table Cell and Gene Therapy in Cardiovascular and Blood Disorders
        • Table Cardiovascular and Blood Disorders Cell and Gene Therapy Approvals by Year, through 2019
    • Trends in Research and Development
      • Table Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Phase (%), March 2020 Data
      • Table Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Method (%), March 2020 Data
      • Phase III Development
        • Table Select Cardiovascular and Blood Disorder Phase III Cell and Gene Therapy Developments, through March 2020
      • Orphan Drug, Fast Track, Breakthrough Designations
        • Table Orphan Drug, Fast Track and Breakthrough Designations for Cardiovascular and Blood Disorder Cell and Gene Therapies in Development (Phase I through III), through March 2020
    • Market Breakdown of Cell and Gene Therapies
      • Table Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions)
      • Table Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, 2017 - 2030 ($ millions)
      • Table Cardiovascular and Blood Disorders Cell and Gene Therapy Market Distribution by Product Type, 2020 (%)
      • Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication
        • Table Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions)
        • Table Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, 2017 - 2030 ($ millions)
        • Table Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication (wound healing/treatment vs. other indications), Estimated 2020 (%)
    • Regional Market Summary
      • Table Cardiovascular and Blood Disorders Cell and Gene Therapy Approvals by Country/Region, through 2019
      • Table Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions)
      • Table Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions)
    • Competitor Summary
  • Cell and Gene Therapy Markets in Oncology
    • Overview
      • Biochemistry of Cancer Cells
    • Causes of Cancer Growth
      • Environmental Factors, DNA, RNA
        • Table Virus Association with Human Cancer
      • Cellular Oncogenes
      • Tumor Suppressor Genes
      • CAR-T Therapies
    • Global Cancer Burden
      • Table Global Cancer Incidence Trends, 2010-2040
      • Table Incidence of Cancer by Type, 2018
      • Table Distribution of Cancer Incidence by Type, 2018
    • Market Outlook
      • Table Cell and Gene Therapy Markets in Oncology, 2019-2030 ($ millions)
    • Principal Products
      • APCeden
      • CreaVax-RCC
      • Gendicine
      • Imlygic
      • Immuncell-LC
      • Kymriah
      • Provenge
      • Yescarta
      • Zalmoxis
        • Table Cell and Gene Therapy in Oncology
        • Table Oncology Cell and Gene Therapy Approvals by Year, through 2019
    • Trends in Research and Development
      • Table Oncology Cell and Gene Therapies in Development by Phase (%), March 2020 Data
      • Table Oncology Cell and Gene Therapies in Development by Method (%), March 2020 Data
      • Table Oncology Cell and Gene Therapy Development by Cancer Type, March 2020 Data (Phase I through Phase III)
      • Phase III Development
        • Table Select Oncology Phase III Cell and Gene Therapy Developments, through March 2020
      • Orphan Drug, Fast Track, Breakthrough Designations
        • Table Orphan Drug, Fast Track and Breakthrough Designations for Oncology Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through March 2020
    • Market Breakdown of Cell and Gene Therapies
      • Table Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions)
      • Table Cell and Gene Therapy Markets by Product Type, 2017 - 2030 ($ millions)
      • Table Oncology Cell and Gene Therapy Market Distribution by Product Type, 2020 (%)
      • Oncology Cell and Gene Therapy Market by Cancer Type
        • Table Oncology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions)
        • Table Oncology Cell and Gene Therapy Market by General Indication, 2017 - 2030 ($ millions)
        • Table Oncology Cell and Gene Therapy Market by General Indication (Blood cancers, Prostate cancer, Melanoma, Other cancers), Estimated 2020 (%)
    • Regional Market Summary
      • Table Oncology Cell and Gene Therapy Approvals by Country/Region, through 2019
      • Table Oncology Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions)
      • Table Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions)
    • Competitor Summary
      • Table Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)
  • Cell and Gene Therapy Markets in Ophthalmic Conditions
    • Overview
    • Market Outlook
      • Table Cell and Gene Therapy Markets in Ophthalmic Conditions, 2019-2030 ($ millions)
    • Principal Products
      • Holoclar
      • Luxturna
        • Table Cell and Gene Therapy in Ophthalmic Conditions
    • Trends in Research and Development
      • Table Ophthalmology Cell and Gene Therapies in Development by Phase (%), March 2020 Data
      • Table Ophthalmology Cell and Gene Therapies in Development by Method (%), March 2020 Data
      • Phase III Development
        • Table Select Ophthalmology Phase III Cell and Gene Therapy Developments, through March 2020
      • Orphan Drug, Fast Track, Breakthrough Designations
        • Table Orphan Drug, Fast Track and Breakthrough Designations for Ophthalmology Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through March 2020
    • Market Breakdown of Cell and Gene Therapies
      • Table Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions)
      • Table Ophthalmology Cell and Gene Therapy Markets by Product Type, 2017 - 2030 ($ millions)
      • Table Ophthalmology Cell and Gene Therapy Market Distribution by Product Type, 2020 (%)
    • Regional Market Summary
      • Table Ophthalmology Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions)
      • Table Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions)
    • Competitor Summary
  • Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders
    • Overview
    • Market Outlook
      • Table Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders, 2019-2030 ($ millions)
    • Principal Products
      • AlloStem
      • BBIO4
      • Carticel
      • Cartiform
      • CartiLife
      • Cartistem
      • ChondroCelect
      • Chondron
      • JACC
      • MACI
      • Ortho-ACI and Ortho-ATI
      • Ossron
      • Osteocel and Osteoplus
      • Spherox
      • Trinity Elite and Trinity Evolution
        • Table Cell and Gene Therapy in Musculoskeletal Diseases and Disorders
        • Table Musculoskeletal Cell Therapy Approvals by Year or Year Range, through 2019
    • Trends in Research and Development
      • Table Musculoskeletal Cell and Gene Therapies in Development by Phase (%), March 2020 Data
      • Table Musculoskeletal Cell and Gene Therapies in Development by Method (%), March 2020 Data
    • Market Breakdown of Cell Therapies
      • Table Musculoskeletal Cell Therapy Market, Estimated 2020 and Projected 2025 and 2030 ($ millions)
      • Table Musculoskeletal Cell Therapy Market, 2017 - 2030 ($ millions)
      • Musculoskeletal Cell Therapy Market by Indication
        • Table Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions)
        • Table Musculoskeletal Cell and Gene Therapy Market by General Indication, 2017 - 2030 ($ millions)
        • Table Musculoskeletal Cell Therapy Market by General Indication (Cartilage treatment, Bone treatment and Other indications), Estimated 2020 (%)
    • Regional Market Summary
      • Table Musculoskeletal Cell Therapy Approvals by Country/Region (%), through 2019
      • Table Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions)
      • Table Musculoskeletal Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions)
    • Competitor Summary
      • Table Musculoskeletal Cell Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)
  • Cell and Gene Therapy Markets in Other Conditions
    • Overview
    • Market Outlook
      • Table Cell and Gene Therapy Markets in Other Conditions, 2019-2030 ($ millions)
    • Principal Products
      • Alofisel
      • Cupistem
      • Givlaari
      • Glybera
      • NeuroNata-R
      • Onpattro
      • Stemirac
      • Strimvelis
      • Temcell/Prochymal
      • Zolgensma
        • Table Cell and Gene Therapy in Other Diseases and Disorders
    • Trends in Research and Development
      • Table Other Conditions and Disorders: Cell and Gene Therapies in Development by Segment and Phase (%), March 2020 Data
    • Market Breakdown of Cell and Gene Therapies
      • Table Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions)
      • Table Other Conditions Cell and Gene Therapy Markets by Product Type, 2017 - 2030 ($ millions)
      • Table Other Conditions Cell and Gene Therapy Market Distribution by Product Type, 2020 (%)
    • Regional Market Summary
      • Table Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions)
      • Table Other Conditions Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions)
    • Competitor Summary
  • Cell and Gene Therapy Market Review
    • Market Influences
      • Global Demographics
        • Table Global Population, through 2050 (population in millions)
        • Table Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
      • Cost Containment
        • Table Cost Comparisons for Commercialized Cell and Gene Therapies
    • Global Market Summary
      • Table Cell and Gene Therapy Market Summary by Product Segment, 2020-2030 ($ millions)
    • Cell vs. Gene Therapy Markets
      • Table Cell and Gene Therapy Market Summary by Method, 2020-2030 ($ millions)
    • Regional Market Overview
      • Table Cell and Gene Therapy Market Summary by Geographical Region, 2020-2030 ($ millions)
    • United States
      • Table Cell and Gene Therapy Market Summary for United States by Product Segment, 2020-2030 ($ millions)
      • Table U.S. Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
      • Table Major Cell and Gene Therapy Product Approvals, FDA
    • Europe/European Union
      • Table Cell and Gene Therapy Market Summary for Europe/European Union by Product Segment, 2020-2030 ($ millions)
      • Table Europe Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
      • Table Major Cell and Gene Therapy Approvals by EMA
    • Other Countries
      • Table Cell and Gene Therapy Market Summary for Other Countries by Product Segment, 2020-2030 ($ millions)
      • Table Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
      • Table Select Major Cell and Gene Therapy Approvals by Various Regulatory Authorities
    • Competitor Ranking in Cell and Gene Therapy Markets
      • Table Estimated Cell and Gene Therapy Sales by Leading Competitor, 2019 Sales ($ millions)
  • Market Participants
    • Leading Influencers
    • Advantagene, Inc.
      • Table Advantagene Corporate Summary
      • Company Summary
      • Products
    • Advaxis, Inc.
      • Table Advaxis Corporate Summary
      • Company Summary
      • Products
    • AlloSource
      • Table AlloSource Corporate Summary
      • Company Summary
      • Products
    • Alnylam Pharmaceuticals
      • Table Alnylam Pharmaceuticals Corporate Summary
      • Company Summary
      • Products
    • Amgen
      • Table Amgen Corporate Summary
      • Company Summary
      • Products
    • AnGes Inc.
      • Table AnGes Corporate Summary
      • Company Summary
      • Products
    • Anterogen Co Ltd.
      • Table Anterogen Corporate Summary
      • Company Summary
      • Products
    • Atara Biotherapeutics
      • Table Atara Biotherapeutics Corporate Summary
      • Company Summary
      • Products
    • Athersys, Inc
      • Table Athersys Corporate Summary
      • Company Summary
      • Products
    • AveXis, Inc.
      • Table AveXis Corporate Summary
      • Company Summary
      • Products
    • BioCardia
      • Table BioCardia Summary
      • Company Summary
      • Products
    • Biogen, Inc.
      • Table Biogen Corporate Summary
      • Company Summary
      • Products
    • BioMarin Pharmaceuticals
      • Table BioMarin Pharmaceuticals Corporate Summary
      • Company Summary
      • Products
      • bluebird bio, Inc.
        • Table bluebird bio Corporate Summary
      • Company Summary
      • Products
    • Brainstorm Cell Therapeutics
      • Table Brainstorm Cell Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Caladrius Biosciences
      • Table Caladrius Biosciences Corporate Summary
      • Company Summary
      • Products
    • Celyad
      • Table Celyad Corporate Summary
      • Company Summary
      • Products
    • Cook Myosite, Inc
      • Table Cook Myosite Corporate Summary
      • Company Summary
      • Products
    • Cytori Therapeutics, Inc
      • Table Cytori Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Dendreon Pharmaceuticals LLC
      • Table Dendreon Corporate Summary
      • Company Summary
      • Products
    • Ferring Pharmaceuticals
      • Table Ferring Pharmaceuticals Corporate Summary
      • Company Summary
      • Products
    • Fibrocell (Castle Creek Biosciences)
      • Table Fibrocell Corporate Summary
      • Company Summary
      • Products
    • Gamida Cell Ltd.
      • Table Gamida Cell Corporate Summary
      • Company Summary
      • Products
    • GenSight Biologics S.A.
      • Table GenSight Biologics Corporate Summary
      • Company Summary
      • Products
    • Gilead Sciences, Inc.
      • Table Gilead Sciences Corporate Summary
      • Company Summary
      • Products
    • Gradalis, Inc
      • Table Gradalis Corporate Summary
      • Company Summary
      • Products
    • Inovio Pharmaceuticals, Inc.
      • Table Inovio Pharmaceuticals Corporate Summary
      • Company Summary
      • Products
    • Kiadis Pharma B.V.
      • Table Kiadis Pharma Corporate Summary
      • Company Summary
      • Products
    • Medeor Therapeutics
      • Table Medeor Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Medipost Co, Ltd.
      • Table Medipost Corporate Summary
      • Company Summary
      • Products
    • Merck & Co., Inc.
      • Table Merck & Co. Corporate Summary
      • Company Summary
      • Products
    • Mesoblast Ltd.
      • Table Mesoblast Corporate Summary
      • Company Summary
      • Products
    • Moderna, Inc
      • Table Moderna Corporate Summary
      • Company Summary
      • Products
    • Neurotech Pharmaceuticals, Inc.
      • Table Neurotech Corporate Summary
      • Company Summary
      • Products
    • Northwest Biotherapeutics, Inc.
      • Table Northwest Biotherapeutics Corporate Summary
      • Company Summary
      • Products
    • Novartis AG
      • Table Novartis Corporate Summary
      • Company Summary
      • Products
    • NuVasive Biologics
      • Table NuVasive Biologics Corporate Summary
      • Company Summary
      • Products
    • Orchard Therapeutics
      • Table Orchard Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Organogenesis
      • Table Organogenesis Corporate Summary
      • Company Summary
      • Products
    • Orthofix Medical Inc.
      • Table Orthofix Corporate Summary
      • Company Summary
      • Products
    • Osiris Therapeutics, Inc.
      • Table Osiris Corporate Summary
      • Company Summary
      • Products
    • Pharmicell
      • Table Pharmicell Corporate Summary
      • Company Summary
      • Products
    • Pluristem Therapeutics, Inc.
      • Table Pluristem Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Quark Pharmaceuticals
      • Table Quark Pharmaceuticals Corporate Summary
      • Company Summary
      • Products
    • Regenerative Medical System
      • Table Regenerative Medical Corporate Summary
      • Company Summary
      • Products
    • Renova Therapeutics
      • Table Renova Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Sangamo Therapeutics
      • Table Sangamo Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Sanofi
      • Table Sanofi Corporate Summary
      • Company Summary
      • Products
    • SOTIO a.s.
      • Table SOTIO Corporate Summary
      • Company Summary
      • Products
    • Spark Therapeutics
      • Table Spark Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Tessa Therapeutics, Ltd.
      • Table Tessa Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Tocagen, Inc.
      • Table Tocagen Corporate Summary
      • Company Summary
      • Products
    • uniQure N.V.
      • Table uniQure Corporate Summary
      • Company Summary
      • Products
    • VBL Therapeutics (Vascular Biogenics Ltd.)
      • Table VBL Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Vericel Corporation
      • Table Vericel Corporate Summary
      • Company Summary
      • Products
    • ViroMed Co Ltd (Helixmith)
      • Table ViroMed Corporate Summary
      • Company Summary
      • Products

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook